Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
1. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:
(a) SEQ ID NO: 8,
(b) SEQ ID NO: 9, and
(c) SEQ ID NO: 14.
2. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:
(a) SEQ ID NO: 12,
(b) SEQ ID NO: 13,
(c) SEQ ID NO: 47, and
(d) SEQ ID NO: 48.
3. An isolated polypeptide chain consisting of the amino acid sequence of SEQ ID NO: 7.
4. An isolated polypeptide chain comprising the amino acid sequence of SEQ ID NO: 8.
5. An isolated polypeptide chain comprising the amino acid sequence of SEQ ID NO: 9.
6. An isolated polypeptide chain comprising the amino acid sequence of SEQ ID NO: 14.
7. An isolated polypeptide chain consisting of the amino acid sequence of SEQ ID NO: 10.
8. An isolated polypeptide chain comprising the amino acid sequence of SEQ ID NO: 12.
9. An isolated polypeptide chain comprising the amino acid sequence of SEQ ID NO: 13.
10. An isolated polypeptide chain comprising the amino acid sequence of SEQ ID NO: 47.
11. An isolated polypeptide chain comprising the amino acid sequence of SEQ ID NO: 48.